↓ Skip to main content

Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab

Overview of attention for article published in Allergy, Asthma & Clinical Immunology, February 2014
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#23 of 924)
  • High Attention Score compared to outputs of the same age (98th percentile)
  • High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news
8 news outlets
blogs
3 blogs
policy
1 policy source
twitter
7 X users
patent
14 patents
googleplus
1 Google+ user

Citations

dimensions_citation
193 Dimensions

Readers on

mendeley
92 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab
Published in
Allergy, Asthma & Clinical Immunology, February 2014
DOI 10.1186/1710-1492-10-7
Pubmed ID
Authors

Philippe Bégin, Tina Dominguez, Shruti P Wilson, Liane Bacal, Anjuli Mehrotra, Bethany Kausch, Anthony Trela, Morvarid Tavassoli, Elisabeth Hoyte, Gerri O’Riordan, Alanna Blakemore, Scott Seki, Robert G Hamilton, Kari C Nadeau

Abstract

Up to 30% of patients with food allergies have clinical reactivity to more than one food allergen. Although there is currently no cure, oral immunotherapy (OIT) is under investigation. Pilot data have shown that omalizumab may hasten the ability to tolerate over 4 g of food allergen protein.

X Demographics

X Demographics

The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 92 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Korea, Republic of 1 1%
United States 1 1%
Argentina 1 1%
Unknown 89 97%

Demographic breakdown

Readers by professional status Count As %
Other 17 18%
Researcher 15 16%
Student > Postgraduate 9 10%
Student > Ph. D. Student 7 8%
Student > Master 7 8%
Other 15 16%
Unknown 22 24%
Readers by discipline Count As %
Medicine and Dentistry 36 39%
Agricultural and Biological Sciences 8 9%
Biochemistry, Genetics and Molecular Biology 6 7%
Pharmacology, Toxicology and Pharmaceutical Science 5 5%
Immunology and Microbiology 5 5%
Other 4 4%
Unknown 28 30%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 83. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 September 2023.
All research outputs
#511,338
of 25,374,647 outputs
Outputs from Allergy, Asthma & Clinical Immunology
#23
of 924 outputs
Outputs of similar age
#4,534
of 235,878 outputs
Outputs of similar age from Allergy, Asthma & Clinical Immunology
#1
of 31 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 924 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.8. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 235,878 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 31 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.